Koshinski Asset Management, Inc. Clovis Oncology, Inc. Transaction History

Koshinski Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 14, 2022	SELL	$2.7 - $4.76 $20,520 - $36,176	-7,600 Closed	0 $0
Q3 2021 Oct 12, 2021	BUY	$4.06 - $5.8 $30,855 - $44,080	7,600 New	7,600 $33,000
Q1 2021 May 06, 2021	SELL	$4.81 - $10.34 $54,112 - $116,325	-11,250 Closed	0 $0
Q4 2020 Mar 30, 2021	BUY	$4.13 - $6.41 $1,032 - $1,602	250 Added 2.27%	11,250 $54,000
Q4 2020 Feb 05, 2021	SELL	$4.13 - $6.41 $83,236 - $129,187	-20,154 Reduced 64.69%	11,000 $54,000
Q4 2020 Feb 02, 2021	BUY	$4.13 - $6.41 $76,834 - $119,251	18,604 Added 148.24%	31,154 $1.23 Million
Q2 2020 Jul 29, 2020	BUY	$5.69 - $9.69 $2,560 - $4,360	450 Added 3.72%	12,550 $85,000
Q1 2020 Apr 30, 2020	SELL	$3.77 - $11.0 $754 - $2,200	-200 Reduced 1.63%	12,100 $77,000
Q4 2019 Jan 29, 2020	BUY	$3.0 - $16.43 $36,900 - $202,089	12,300 New	12,300 $125,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Koshinski Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Koshinski Asset Management, Inc. with notifications on news.